Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
Earnings Data
Report Date
May 19, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.2Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial picture: very strong top-line growth (123% YoY for FY2025), record Q4 results, robust prescription momentum, expanded approvals and encouraging pediatric Phase II data, improved profitability and positive cash flow, and raised 2026 guidance. Offsetting risks include higher SG&A/R&D investment leading to elevated operating expenses, quarter-to-quarter seasonal and gross-to-net variability (notably a Q1 headwind), limited Medicare Part D coverage with non-preferred tier placement, and execution/timing risk as the company scales its sales force and primary care efforts. Overall, the company appears to be scaling successfully while mindful of near-term investment-driven expense and access nuances.Company Guidance
Strong Revenue Growth (Full Year)
Net product revenues for full year 2025 were $372.1 million, a 123% increase versus 2024, driven primarily by ZORYVE demand across indications.
Record Fourth Quarter Performance
Q4 2025 net product revenues were $127.5 million, up 84% year-over-year and 29% sequentially from Q3 2025; sequential growth driven by a 19% increase in prescription volume in the quarter.
Prescription Momentum and Market Share
Total prescription volume roughly doubled year-over-year in 2025; weekly prescriptions (4-week rolling average) reached ~22,000 scripts. ZORYVE holds ~45% share of branded nonsteroidal topical prescription volume.
Regulatory and Label Expansion Progress
FDA approvals in 2025 included ZORYVE foam 0.3% for scalp and body psoriasis (12+) and ZORYVE cream 0.05% for atopic dermatitis in children 2–5. sNDA submitted for ZORYVE cream 0.3% in psoriasis ages 2–5 with a PDUFA date of June 29, 2026.
Positive Pediatric Phase II Results (INTEGUMENT-INFANT)
Phase II infants (3–24 months) topline: 58% achieved EASI-75 at week 4 and ~33% reached EASI-75 by week 2. No treatment-emergent serious adverse events and only one discontinuation; plan to submit sNDA in Q2 2026.
Pipeline Expansion and New Programs
Initiated Phase II proof-of-concept studies for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa (HS); IND submitted for ARQ-234 (novel biologic) with Phase I dosing expected soon.
Improved Profitability and Cash Flow
Company achieved positive cash flow from operations in Q4 2025 of $26.2 million and reported cash and marketable securities of $221.3 million as of Dec 31, 2025. Net loss for 2025 narrowed to $16.1 million vs. $140.0 million in 2024; Q4 net income was $17.4 million.
Commercial and Access Wins
Expanded commercial footprint (dermatology sales force +20% to ~160 reps) and built an initial primary care/pediatrics pilot (~30 reps). Access: >80% commercial formularies, >50% Medicaid with single-step edits, and ~1/3 of Medicare Part D plans covering ZORYVE (only branded nonsteroidal topical on some Medicare formularies).
Raised 2026 Revenue Guidance
Full year 2026 net product revenue guidance increased from $455–470 million to $480–495 million based on Q4 momentum and planned investments.
ARQT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARQT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $27.01 | $28.57 | +5.78% |
Oct 01, 2025 | $18.85 | $19.76 | +4.83% |
Aug 06, 2025 | $15.36 | $14.12 | -8.07% |
May 06, 2025 | $14.32 | $13.70 | -4.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcutis Biotherapeutics (ARQT) report earnings?
Arcutis Biotherapeutics (ARQT) is schdueled to report earning on May 19, 2026, After Close (Confirmed).
What is Arcutis Biotherapeutics (ARQT) earnings time?
Arcutis Biotherapeutics (ARQT) earnings time is at May 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARQT EPS forecast?
ARQT EPS forecast for the fiscal quarter 2026 (Q1) is -0.04.